Indeed, radiotherapy followed by the intratumoral injection of IL-2 and a tumor-specific monoclonal antibody into the tumor irradiated site (3xTx) can increase the in situ vaccination by recruiting NK cells. The gene discussed is IL2; the disease is neoplasm.